+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
O

Actively Recruiting

Researchers are evaluating the effects and safety of two different doses of rilzabrutinib in adults with Graves disease, including those with and without Graves orbitopathy. This Phase 2, randomized, open-label study aims to better understand how rilzabrutinib impacts thyroid hormone levels in this population. The study is sponsored by Sanofi and involves a parallel group design with two treatment arms. Participants will receive either rilzabrutinib dose 1 or rilzabrutinib dose 2, both administered orally as tablets. The study includes a screening period lasting up to 4 weeks, followed by a treatment period of up to 16 weeks during which participants will take the assigned dose. After treatment, there is a 4-week follow-up period to monitor safety and treatment effects. Throughout the study, participants may have up to 13 visits. Participants will undergo assessments including measurements of thyroid hormone levels such as free thyroxine FT4 and free triiodothyronine FT3 at baseline and Week 16. Safety is monitored by tracking adverse events throughout the study and follow-up period. Researchers will analyze changes in hormone levels and the proportion of participants achieving normal thyroid levels. The total participation duration is approximately 24 weeks including screening, treatment, and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
24 locations
C

Actively Recruiting

This clinical trial investigates the best way to use prone position placing patients on their stomachs for adults with moderate to severe Acute Respiratory Distress Syndrome ARDS who need mechanical ventilation. Researchers want to find out if longer prone sessions lasting more than 48 hours improve survival compared to daily sessions lasting 16 to 24 hours. The study also evaluates the safety of prolonged prone positioning and its impact on medical problems related to this intervention. Participants are randomly assigned to one of two groups one receiving prolonged prone position sessions lasting at least 48 hours and up to 120 hours until their oxygenation improves, and the other receiving intermittent daily prone sessions lasting between 16 and 24 hours. Both groups may have repeated prone sessions during the first 7 days if their oxygen levels fall below a certain threshold after returning to the supine position. This design allows comparison of continuous versus intermittent prone positioning in managing ARDS. During the study, participants will be followed for up to 90 days to monitor their clinical progress. Researchers will assess outcomes including mortality at 28 and 90 days, ventilator-free days, and hospital-free days at 28 days. Safety and adverse events related to prone positioning will also be recorded. The total participation involves receiving the assigned prone sessions during the first week and ongoing clinical follow-up to evaluate the effectiveness and safety of each approach.

Age: 18Years +All GendersPhase Not Applicable
38 locations
F

Actively Recruiting

Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.

All AgesAll Genders
284 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of RO7771950 combined with trastuzumab and capecitabine compared to tucatinib with trastuzumab and capecitabine in people with locally advanced or metastatic HER2-positive breast cancer. This study includes patients with or without brain metastases and aims to provide new insights into treatments for this serious condition. The trial is a randomized, open-label study sponsored by Hoffmann-La Roche and involves multiple centers. Participants will be assigned to one of three groups two groups receive different doses of RO7771950 orally twice a day along with trastuzumab and capecitabine, while the third group receives tucatinib orally twice a day with the same combination of trastuzumab and capecitabine. Trastuzumab is given either intravenously or subcutaneously according to local guidelines, and capecitabine is taken orally twice daily. The study includes two parts and is designed to adapt as it progresses to ensure the best evaluation of treatments. During the trial, participants will be closely monitored through various assessments including imaging to measure tumor progression, quality of life evaluations, and safety checks such as heart function tests and monitoring of side effects. The main measure of success is progression-free survival over about 35 months. Other outcomes include overall survival, response rates, and symptom changes, with follow-ups continuing up to about 53 months. Participants will have regular visits for treatment and evaluations throughout the study period.

Age: 18Years +All GendersPhase 2Phase 3
206 locations